Skip to main content
. Author manuscript; available in PMC: 2019 Jan 8.
Published in final edited form as: Cancer Cell. 2018 Jan 8;33(1):108–124.e5. doi: 10.1016/j.ccell.2017.12.001

Figure 4. Oncogenic KRAS drives angiosarcoma in aP2-Cre expressing cells.

Figure 4

(A) Kaplan-Meier survival curve illustrating survival of aP2-Cre;LSL-KrasG12D;Cdkn2aFlox/Flox(n = 24) and aP2-Cre;LSL-KrasG12D(n = 10) mice. p < 0.0001.

(B) Percentage of aP2-Cre;LSL-KrasG12D;Cdkn2aFlox/Flox mice developing angiosarcoma or other malignancies.

(C) Angiosarcomas (arrowheads) in aP2-Cre;LSL-KrasG12D;Cdkn2aFlox/Flox mice.

(D) Representative H&E staining and IHC of angiosarcoma markers in aP2-Cre;LSL-KrasG12D;Cdkn2aFlox/Flox tumors(n = 6). Scale bars, 50 μm.

See also Figure S4.